Pergolide mesylate is a methanesulfonate salt obtained from pergolide by mixing eqimolar amount of pergolide and methanesulfonic acid. A dopamine D2 receptor agonist which also has D1 and D2 agonist properties, it is used in the management of Parkinson’s disease, although it was withdrawn from the U.S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction. It is grouped under the following drug class(es): Dopamine agents and Neurotransmitter agents. The directory classifies it as a discontinued API with a synthetic source/manufacturing origin. Other names for this substance include Prascend, Celance, Pharken and Nopar. Its PubChem CID is 47812.
Pergolide mesylate
| CAS No | 66104-23-2 |
|---|---|
| Molecular Formula | C20H30N2O3S2 |
| Molecular Weight | 410.6 g/mol |
| Synonyms | (6aR,9R,10aR)-9-(methylsulfanylmethyl)-7-propyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline;methanesulfonic acid |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Pergolide mesylate is a methanesulfonate salt obtained from pergolide by mixing eqimolar amount of pergolide and methanesulfonic acid. S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction.
The listed CAS number is 66104-23-2.
The listed molecular formula is C20H30N2O3S2.
The listed molecular weight is 410.6 g/mol.
(6aR,9R,10aR)-9-(methylsulfanylmethyl)-7-propyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline;methanesulfonic acid.
The source lists Prascend, Celance, Pharken and Nopar.